BOSTON, MA, July 21, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials® platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. The solution offers real-time and aggregated analytics allowing sponsors and PAREXEL® clinical research professionals to detect key signals and trends. The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.
“As clinical studies become more complex, there is a growing need for real-time and standardized data and analytics from multiple studies,” said Xavier Flinois, President, PAREXEL Informatics. “Using the enhanced tools available with the Perceptive MyTrials Analytics solution, our clients can visualize trends across studies, garner reliable intelligence, and confidently make data-driven business decisions. This information will ultimately help reduce risk, increase clinical trial efficiency, and speed time to market for our clients and for patients.”
Developed by PAREXEL Informatics, the Perceptive MyTrials® platform provides an integrated suite of applications for managing clinical trials. Perceptive MyTrials Analytics offers enhanced analytics capabilities and cross-study business intelligence from within the Perceptive MyTrials platform.
Flinois added, “At PAREXEL, our mission is to bring science to the real world by simplifying a client’s journey at every step. Perceptive MyTrials Analytics is another example of the integrated solutions we are developing that incorporate optimized study management processes that leverage mobile and analytics as part of our broader ‘SMAC’ [social media, mobile, analytics, and cloud] technology approach.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.